Maynard Um
-
-
-
-
-
-
-
Silexion plans phase 2/3 trial for cancer drug in first half of 2026
-
-
-
-
-
-
-
Silexion Therapeutics implements 1-for-15 reverse stock split
-
-
-
-
-
-
-
Silexion Therapeutics (SLXN) Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models
-
-
-
-
-
-
434,146 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

